Model‐informed bridging of rivaroxaban doses for thromboprophylaxis in pediatric patients aged 9 years and older with congenital heart disease

Rivaroxaban is approved in various regions for the treatment of acute venous thromboembolism (VTE) in children aged between 0 and 18 years and was recently investigated for thromboprophylaxis in children aged between 2 and 8 years (with body weights

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	CPT: Pharmacometrics & Systems Pharmacology 2022-08, Vol.11 (8), p.1111-1121
Hauptverfasser:	Willmann, Stefan, Ince, Ibrahim, Ahsman, Maurice, Coboeken, Katrin, Zhang, Yang, Thelen, Kirstin, Kubitza, Dagmar, Zannikos, Peter, Zhou, Wangda, Pina, Liza Miriam, Post, Teun, Lippert, Jörg
Format:	Artikel
Sprache:	eng
Schlagworte:	Adults Age Analysis Body weight Bone surgery Cardiovascular disease Care and treatment Children Congenital diseases Congenital heart disease Drug dosages Genetic disorders Health aspects Heart diseases Orthopedics Pediatrics Pharmacokinetics Population Rivaroxaban Simulation Simulation methods Thromboembolism
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Rivaroxaban is approved in various regions for the treatment of acute venous thromboembolism (VTE) in children aged between 0 and 18 years and was recently investigated for thromboprophylaxis in children aged between 2 and 8 years (with body weights
ISSN:	2163-8306 2163-8306
DOI:	10.1002/psp4.12830